We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-12.58%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$3.2B
AUM Growth
+$58.8M
Cap. Flow
+$623M
Cap. Flow %
19.5%
Top 10 Hldgs %
58.78%
Holding
99
New
23
Increased
20
Reduced
15
Closed
12

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$158M
2
ZLAB icon
Zai Lab
ZLAB
+$107M
3
ARVN icon
Arvinas
ARVN
+$93.6M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$70.9M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$59.4M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$81.7M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$77.3M
3
RCUS icon
Arcus Biosciences
RCUS
+$75.7M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$63.6M
5
ITOS
iTeos Therapeutics
ITOS
+$44.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.15%
2 Financials 0.61%
3 Miscellaneous 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$479M
$424M 13.25%
11,584,280
+300,000
+3% +$10.8M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$263M 8.24%
5,183,431
+1,149,549
+28% +$50.7M
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$198M 6.2%
3,195,624
+971,221
+44% +$59.4M
ANAB icon
4
AnaptysBio
ANAB
$1.67B
$186M 5.82%
7,521,024
– –
SRPT icon
5
Sarepta Therapeutics
SRPT
$2.2B
$162M 5.06%
+2,069,634
New +$158M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$159M 4.96%
3,951,566
– –
ACAD icon
7
Acadia Pharmaceuticals
ACAD
$5.02B
$145M 4.54%
5,991,479
+2,930,886
+96% +$70.9M
XNCR icon
8
Xencor
XNCR
$1.94B
$133M 4.15%
4,968,756
+62,650
+1% +$2.02M
KURA icon
9
Kura Oncology
KURA
$1.13B
$107M 3.34%
6,638,371
+2,913,934
+78% +$42.1M
RCUS icon
10
Arcus Biosciences
RCUS
$3.72B
$103M 3.22%
3,265,101
-2,258,257
-41% -$75.7M
ARVN icon
11
Arvinas
ARVN
$600M
$101M 3.17%
1,503,929
+1,373,629
+1,054% +$93.6M
ZLAB icon
12
Zai Lab
ZLAB
$2.93B
$97.8M 3.06%
+2,223,212
New +$107M
ALEC icon
13
Alector
ALEC
$261M
$81.8M 2.56%
5,738,448
+743,478
+15% +$11.8M
NUVB icon
14
Nuvation Bio
NUVB
$2.34B
$73.1M 2.29%
13,896,543
– –
RLAY icon
15
Relay Therapeutics
RLAY
$4.11B
$68.6M 2.15%
2,291,441
+512,357
+29% +$12.4M
RETA
16
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$64.7M 2.02%
+1,975,611
New +$58.6M
TSVT
17
DELISTED
2seventy bio
TSVT
$59.6M 1.87%
3,495,943
+1,578,880
+82% +$26.8M
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$57.6M 1.8%
+1,646,260
New +$48.1M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$51M 1.59%
2,759,505
– –
AVIR icon
20
Atea Pharmaceuticals
AVIR
$430M
$45.8M 1.43%
6,340,639
+964,505
+18% +$6.55M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.2M 1.29%
+500,622
New +$51.2M
ARGX icon
22
argenx
ARGX
$64B
$39.4M 1.23%
+125,000
New +$36.3M
DSGN icon
23
Design Therapeutics
DSGN
$946M
$38.3M 1.2%
2,371,445
+218,448
+10% +$3.35M
RVMD icon
24
Revolution Medicines
RVMD
$44.6B
$32.5M 1.02%
+1,274,097
New +$27.7M
PCVX icon
25
Vaxcyte
PCVX
$8.9B
$31.5M 0.99%
1,304,741
+1,283,941
+6,173% +$28.1M
1
2 3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2022 Portfolio in Review

As of Q1 2022, EcoR1 Capital held 99 positions worth $3.2B, up 1.9% from $3.14B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

EcoR1 Capital deployed $623M of net new capital in Q1 2022, opening 23 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 2,069,634 shares worth $162M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $75.7M trimmed.

  • EcoR1 Capital's largest Q1 2022 buy was Sarepta Therapeutics: 2,069,634 shares worth $162M.
  • EcoR1 Capital added most to Arvinas in Q1 2022, an estimated $93.6M increase.
  • EcoR1 Capital's biggest Q1 2022 reduction was Arcus Biosciences, cutting an estimated $75.7M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q1 2022, selling an estimated $81.7M.
  • EcoR1 Capital's ten largest holdings make up 59% of its $3.2B portfolio in Q1 2022.
  • EcoR1 Capital opened 23 new positions and closed 12 in Q1 2022.
  • EcoR1 Capital's portfolio value rose 1.9% quarter-over-quarter to $3.2B.

Based on EcoR1 Capital's 13F filing for Q1 2022, filed 16 May 2022.